Salmedix Files for IPO

San Diego-based Salmedix has filed to raised up to $86M in an IPO. Salmedix is developing oncology drugs initially targeted at hematologic cancers, and is pre-revenue and is not expected to generate any revenue from the sale of its lead drug candidate for the foreseeable future. The IPO is being underwritten by SG Cowen, JMP Securities, Pacific Growth Equities, and ThinkEquity Partners. More information »